February 22, 2023 02:37 PM EST
Pharma
Marketing

Boehringer In­gel­heim broad­casts third pod­cast sea­son around rare lung con­di­tion

Beth Snyder Bulik

Senior Editor

Boehringer In­gel­heim is back on the pod­cast au­dio waves with the next sea­son of its pul­monary fi­bro­sis se­ries.

In its third sea­son, Boehringer is part­ner­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times